Sitagliptin in the treatment of type 2 diabetes: a meta-analysis
- PMID:23672222
- DOI: 10.1111/j.1756-5391.2012.01189.x
Sitagliptin in the treatment of type 2 diabetes: a meta-analysis
Abstract
Objective: To evaluate the benefits and harms of sitagliptin in people with type 2 diabetes mellitus.
Methods: Randomized controlled trials (RCTs) were retrieved from PubMed, Embase, and the Cochrane central register of controlled trials (Cochrane Library). We used the method recommend by the Cochrane Collaboration to perform a meta-analysis of RCTs of sitagliptin therapy for type 2 diabetes.
Results: Of 817 studies retrieved in the literature search, 18 were eligible for inclusion. When sitagliptin was compared with placebo there was a statistically significant reduction in haemoglobin A1C (HbA1c) (MD = 0.74, 95% CI 0.63 to 0.85) and fasting plasma glucose (FPG) (MD = 1.20, 95% CI 1.03 to 1.38). Sitagliptin significantly improved the homeostasis model assessment of β-cell (HOMA-β index) (MD =-10.84, 95% CI -14.07 to -7.80) versus placebo. In participants treated with placebo, hypoglycemia adverse experiences (RR = 2.11, 95% CI 1.50 to 2.36) and serious adverse experiences (RR = 1.20, 95% CI 0.89 to 1.63) were less common. Meta-analysis did not show a significant difference in change in FPG (MD =-0.32, 95% CI -0.76 to 0.13) or HOMA-β index (MD = 4.42, 95% CI -1.22 to 10.07) between the sitagliptin and active control groups, but active treatments provided modestly greater reduction in HbA1c (MD =-0.20, 95% CI -0.37 to -0.03) compared with sitagliptin. No significant difference was observed between the sitagliptin and active treatments in incidence of hypoglycemia adverse experiences (RR = 0.38, 95% CI 0.14 to 1.08) or serious adverse experiences (RR = 1.15, 95% CI 0.83 to 1.65).
Conclusions: Sitagliptin treatment for type 2 diabetes was effective and well tolerated. Sitagliptin offers a novel therapeutic approach for the treatment of type 2 diabetes. Continued assessment in longer term studies is required to determine the role of sitagliptin in type 2 diabetes.
© 2012 Wiley Publishing Asia Pty Ltd and Chinese Cochrane Center, West China Hospital of Sichuan University.
Similar articles
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.Hermansen K, et al.Diabetes Obes Metab. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. Epub 2007 Jun 26.Diabetes Obes Metab. 2007.PMID:17593236Clinical Trial.
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.Rosenstock J, et al.Clin Ther. 2006 Oct;28(10):1556-68. doi: 10.1016/j.clinthera.2006.10.007.Clin Ther. 2006.PMID:17157112Clinical Trial.
- Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.Brazg R, et al.Diabetes Obes Metab. 2007 Mar;9(2):186-93. doi: 10.1111/j.1463-1326.2006.00691.x.Diabetes Obes Metab. 2007.PMID:17300594Clinical Trial.
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.Derosa G, et al.Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.Metabolism. 2010.PMID:20015525Clinical Trial.
- Sitagliptin: a novel drug for the treatment of type 2 diabetes.Choy M, Lam S.Choy M, et al.Cardiol Rev. 2007 Sep-Oct;15(5):264-71. doi: 10.1097/CRD.0b013e318123f771.Cardiol Rev. 2007.PMID:17700385Review.
Cited by
- DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.Yu SJ, Wang Y, Shen H, Bae EK, Li Y, Sambamurti K, Tones MA, Zaleska MM, Hoffer BJ, Greig NH.Yu SJ, et al.Geroscience. 2024 Oct;46(5):4349-4371. doi: 10.1007/s11357-024-01116-0. Epub 2024 Apr 2.Geroscience. 2024.PMID:38563864Free PMC article.
- Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial.Zhou XJ, Ding L, Liu JX, Su LQ, Dong JJ, Liao L.Zhou XJ, et al.Endocr Connect. 2019 Apr;8(4):318-325. doi: 10.1530/EC-18-0523.Endocr Connect. 2019.PMID:30822272Free PMC article.
- Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice.Yang F, Dang S, Lv H, Shi B.Yang F, et al.J Int Med Res. 2021 Jan;49(1):300060520985664. doi: 10.1177/0300060520985664.J Int Med Res. 2021.PMID:33512261Free PMC article.
- Effect of a low dose whey/guar preload on glycemic control in people with type 2 diabetes--a randomised controlled trial.Clifton PM, Galbraith C, Coles L.Clifton PM, et al.Nutr J. 2014 Oct 25;13:103. doi: 10.1186/1475-2891-13-103.Nutr J. 2014.PMID:25343850Free PMC article.Clinical Trial.
- The association between CD14-260C/T polymorphism and malignant tumor risk: a meta-analysis of 5,603 participants.Tong X, Li Z, Fu X, Zhou K, Wu Y, Zhang Y, Fan H.Tong X, et al.Tumour Biol. 2014 Sep;35(9):8707-13. doi: 10.1007/s13277-014-2040-8. Epub 2014 May 29.Tumour Biol. 2014.PMID:24870592
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical